Oncology Briefings™: Best Practices for the Prevention and Management of Tumor Lysis Syndrome

Release Date: April 30, 2020
Expiration Date: April 30, 2021

Activity Overview

This online activity is designed to provide a concise and focused overview on an important clinical topic and includes information on the diagnosis and risk stratification of tumor lysis syndrome (TLS), evidence-based recommendations on the prophylaxis and treatment of TLS, and unmet medical needs in the management of TLS. The engaging, multimedia format of this program includes audio commentary from an expert thought leader integrated with text-based elements.

Acknowledgement of Support

This activity is supported by an educational grant from Sanofi Genzyme.

Target Audience

This educational initiative is directed toward medical oncologists and hematologists who treat patients with hematologic malignancies. Nephrologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, fellows, and other healthcare professionals interested in the treatment and prevention of TLS will also be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Identify risk factors in pediatric and adult patients who could potentially develop tumor lysis syndrome
• Describe optimal prophylactic strategies for patients with TLS based on individual risk
• Apply evidence-based recommendations for the treatment of TLS in patients with cancer

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Anthony Mato, MD, MSCE
Director, Chronic Lymphocytic Leukemia Program
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant Research Support: Adaptive Biotechnologies, DTRM Biopharma, Johnson & Johnson, Loxo Oncology, Pharmacyclics, Regeneron, Sunesis, TG Therapeutics; Consultant: Adaptive, AstraZeneca, Celgene, Johnson & Johnson, Loxo Oncology, Pharmacyclics, Regeneron, Sunesis, TG Therapeutics.

The staff Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.